UK – NICE evidence request for Blincyto for acute lymphoblastic leukaemia

The National Institute for Health and Care Excellence (NICE) has requested further evidence on Amgen’s Blincyto (blinatumomab) for the treatment of adults with acute lymphoblastic leukaemia.

The committee concluded that Blincyto has significant clinical benefits, but that further evidence on cost-effectiveness is required to assess its plausibility for NHS funding. NICE has requested further clarification from the company for the second committee meeting in April.

The drug first won conditional clearance for use in adults in November 2015, which was converted to full approval in June last year on the back of data from the Phase III TOWER study, in which it showed a superior improvement in median overall over standard of care chemotherapy (7.7 months versus four months, respectively).

Blincyto is an example of a BiTE antibody construct, a type of immunotherapy designed to help the body’s immune system to detect and target malignant cells…